Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Assembly Biosciences

Assembly Biosciences (NASDAQ: ASMB) insider transactions

In the twelve months to 10 November 2026, executives and directors of Assembly Biosciences reported 13 open-market sales of 12,669 shares ($252,334) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Assembly Biosciences shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
2 November 2026Okazaki Jason ACEO and PresidentOpen-market sale−6,133$19.61195,601Form 4
2 November 2026Okazaki Jason ACEO and PresidentOpen-market sale−69$20.35195,532Form 4
2 November 2026Gaggar AnujChief Medical OfficerOpen-market sale−2,564$19.6153,829Form 4
2 November 2026Gaggar AnujChief Medical OfficerOpen-market sale−29$20.3553,800Form 4
2 November 2026White Nicole SChief Manufacturing OfficerOpen-market sale−2,564$19.6159,286Form 4
2 November 2026White Nicole SChief Manufacturing OfficerOpen-market sale−29$20.3559,257Form 4
2 November 2026Bjorkquist Jeanette MPFO and PAOOpen-market sale−718$19.6117,682Form 4
2 November 2026Bjorkquist Jeanette MPFO and PAOOpen-market sale−9$20.3517,673Form 4
30 October 2026Okazaki Jason ACEO and PresidentGrant or award+38,380—201,734Form 4
30 October 2026Gaggar AnujChief Medical OfficerGrant or award+13,705—56,393Form 4
30 October 2026Delaney William E IVChief Scientific OfficerGrant or award+13,705—74,035Form 4
30 October 2026White Nicole SChief Manufacturing OfficerGrant or award+13,705—61,850Form 4
30 October 2026Bjorkquist Jeanette MPFO and PAOGrant or award+3,840—18,400Form 4
17 June 2026Bjorkquist Jeanette MPFO and PAOOpen-market sale−29$23.2514,560Form 4
26 May 2026Gilead Sciences, Inc.—Grant or award+471,698$26.504,977,089Form 4
30 March 2026White Nicole SChief Manufacturing OfficerOpen-market sale−188$26.6537,486Form 4
30 March 2026White Nicole SChief Manufacturing OfficerOpen-market sale−9$27.4937,477Form 4
30 March 2026Bjorkquist Jeanette MPFO and PAOOpen-market sale−312$26.6511,105Form 4
30 March 2026Bjorkquist Jeanette MPFO and PAOOpen-market sale−16$27.4911,089Form 4
29 March 2026Okazaki Jason ACEO and PresidentGrant or award+50,750—163,354Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Assembly Biosciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.